Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with lewy bodies and Parkinson's disease dementia

Dementia and Geriatric Cognitive Disorders

Volumn 26, Issue 4, 2008, Pages 330-338

  Sharp, Sally I ^a   Ballard, Clive G ^a   Ziabreva, Iryna ^b   Piggott, Margaret A ^b   Perry, Robert H ^b   Perry, Elaine K ^b   Aarsland, Dag ^c,d   Ehrt, Uwe ^c   Larsen, Jan P ^c,d   Francis, Paul T ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cortex; Dementia; Depression; Lewy body dementia; Parkinson's disease dementia; Serotonin 1A receptors

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; SEROTONIN 1A RECEPTOR;

ARTICLE; AUTOPSY; BRAIN MEMBRANE; DEPRESSION; DIFFUSE LEWY BODY DISEASE; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; SEROTONIN BRAIN LEVEL; TEMPORAL CORTEX;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; AUTOPSY; CEREBRAL CORTEX; DEMENTIA; DEPRESSION; FEMALE; HUMANS; LEVODOPA; LEWY BODY DISEASE; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; TEMPORAL LOBE;

EID: 54749151102     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000161058     Document Type: Article

References (44)

1. Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D - a generic quality of life measure - is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.
2. Ebmeier KP, Donaghey C, Steele JD: Recent developments and current controversies in depression. Lancet 2006;367:153-167.
3. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB: Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004;52:784-788.
4. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
5. McKeith IG, Burn DJ, Ballard CG, Collerton D, Jaros E, Morris CM, McLaren A, Perry EK, Perry R, Piggott MA, O'Brien JT: Dementia with Lewy bodies. Semin Clin Neuropsychiatry 2003;8:46-57.
6. Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, Lantos P, Perry E, Ince P, Perry R: Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry 1999;156:1039-1045.
7. Wermuth L: A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease. Eur J Neurol 1998;5:235-242.
8. Hindmarch I: Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002;17(suppl 3):294-299.
9. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT: Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 1996;66:1592-1598.
10. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK: Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
11. Artigas F, Adell A, Celada P: Pindolol augmentation of antidepressant response. Curr Drug Targets 2006;7:139-147.
12. Meltzer CC, Price JC, Mathis CA, Butters MA, Ziolko SK, Moses-Kolko E, Mazumdar S, Mulsant BH, Houck PR, Lopresti BJ, Weissfeld LA, Reynolds CF: Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology 2004;29:2258-2265.
13. 11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000;57:174-180.
14. Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, Meltzer HY: Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 1997;16:162-173.
15. 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006;59:106-113.
16. Francis PT, Pangalos MN, Stephens PH, Bartlett JR, Bridges PK, Malizia AL, Neary D, Procter AW, Thomas DJ, Bowen DM: Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression. J Neurol Neurosurg Psychiatry 1993;56:80-84.
17. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR: Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 2003;23:8788-8799.
18. Shabnam GN, Th C, Kho D, H R, Ce C: Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003, Art No CD003465.
19. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M: Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002;59:1714-1720.
20. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
21. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
22. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271-284.
23. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
24. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG: Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-1092.
25. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
26. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, Francis PT: Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000;55:1460-1467.
27. Lai MK, Tsang SW, Francis PT, Keene J, Hope T, Esiri MM, Spence I, Chen CP: Post-mortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 2002;13:1175-1178.
28. Ballard C, Ziabreva I, Perry R, Larsen JP, O'Brien J, McKeith I, Perry E, Aarsland D: Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934.
29. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ: Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann NY Acad Sci 1998;861:288-289.
30. 11C-WAY 100635 PET study. Neurology 2003;60:601-605.
31. 3H]imipramine binding sites in control and parkinsonian brains. Eur J Pharmacol 1985;117:71-80.
32. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB: Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-385.
33. Jellinger KA: Post mortem studies in Parkinson's disease: is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999;56:1-29.
34. Benarroch EE, Schmeichel AM, Low PA, Boeve BF, Sandroni P, Parisi JE: Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain 2005;128:338-344.
35. Walter U, Dressler D, Wolters A, Wittstock M, Greim B, Benecke R: Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia. J Neurol 2006;253:448-454.
36. Ohara K, Kondo N, Ohara K: Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:311-317.
37. Perry EK, Marshall E, Thompson P, McKeith IG, Collerton D, Fairbairn AF, Ferrier IN, Irving D, Perry RH: Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J Neural Transm Park Dis Dement Sect 1993;6:167-177.
38. Ballard C, Johnson M, Piggott M, Perry R, O'Brien J, Rowan E, Perry E, Lantos P, Cairns N, Holmes C: A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. J Affect Disord 2002;69:219-223.
39. Mayeux R: The 'serotonin hypothesis' for depression in Parkinson's disease. Adv Neurol 1990;53:163-166.
40. Delgado PL, Price LH, Miller HL, Salomon RM, Aghajanian GK, Heninger GR, Charney DS: Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874.
41. 1A receptors from bovine hippocampus by an agonist and an antagonist. FEBS Lett 1999;457:389-392.
42. 2 receptors in the rat orbitofrontal cortex after long-term serotonin reuptake inhibition. J Psychiatry Neurosci 2005;30:268-274.
43. Zhou L, Huang KX, Kecojevic A, Welsh AM, Koliatsos VE: Evidence that serotonin reuptake modulators increase the density of serotonin innervation in the forebrain. J Neurochem 2006;96:396-406.
44. 1A receptors. J Neurosci 1998;18:10150-10156.